Literature DB >> 16875817

Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.

Veemal Bhowruth1, Alistair K Brown, Robert C Reynolds, Geoffrey D Coxon, Simon P Mackay, David E Minnikin, Gurdyal S Besra.   

Abstract

Symmetrical and unsymmetrical analogues of the antimycobacterial agent isoxyl have been synthesized and tested against Mycobacterium tuberculosis H37Rv and Mycobacterium bovis BCG, some showing an increased bactericidal effect. In particular, compounds 1-(p-n-butylphenyl)-3-(4-propoxy-phenyl) thiourea (10) and 1-(p-n-butylphenyl)-3-(4-n-butoxy-phenyl) thiourea (11) showed an approximate 10-fold increase in in vitro potency compared to isoxyl, paralleled by increased inhibition of mycolic acid biosynthesis in M. bovis BCG. Interestingly, these isoxyl analogues showed relatively poor inhibition of oleate production, suggesting that the modifications have changed the spectrum of biological activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16875817     DOI: 10.1016/j.bmcl.2006.06.095

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles.

Authors:  Chenchen Wang; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2010-03-26       Impact factor: 3.246

2.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.

Authors:  Subramaniam Ananthan; Ellen R Faaleolea; Robert C Goldman; Judith V Hobrath; Cecil D Kwong; Barbara E Laughon; Joseph A Maddry; Alka Mehta; Lynn Rasmussen; Robert C Reynolds; John A Secrist; Nice Shindo; Dustin N Showe; Melinda I Sosa; William J Suling; E Lucile White
Journal:  Tuberculosis (Edinb)       Date:  2009-09-15       Impact factor: 3.131

3.  Phenylethyl butyrate enhances the potency of second-line drugs against clinical isolates of Mycobacterium tuberculosis.

Authors:  Thomas Grau; Petra Selchow; Marcel Tigges; Reto Burri; Marc Gitzinger; Erik C Böttger; Martin Fussenegger; Peter Sander
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

4.  Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis.

Authors:  Jana Korduláková; Yves L Janin; Avraham Liav; Nathalie Barilone; Tiago Dos Vultos; Jean Rauzier; Patrick J Brennan; Brigitte Gicquel; Mary Jackson
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

Review 5.  The mycobacterial cell envelope-lipids.

Authors:  Mary Jackson
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-07       Impact factor: 6.915

Review 6.  Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.

Authors:  Mary Jackson; Michael R McNeil; Patrick J Brennan
Journal:  Future Microbiol       Date:  2013-07       Impact factor: 3.165

Review 7.  New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics.

Authors:  E Jeffrey North; Mary Jackson; Richard E Lee
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Authors:  Lynn G Dover; Anuradha Alahari; Paul Gratraud; Jessica M Gomes; Veemal Bhowruth; Robert C Reynolds; Gurdyal S Besra; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

9.  Synthesis, docking study and biological evaluation of some new thiourea derivatives bearing benzenesulfonamide moiety.

Authors:  Mostafa M Ghorab; Mohamed S A El-Gaby; Aiten M Soliman; Mansour S Alsaid; Marwa M Abdel-Aziz; Mahmoud M Elaasser
Journal:  Chem Cent J       Date:  2017-05-19       Impact factor: 4.215

10.  Investigation of the reactivity properties of a thiourea derivative with anticancer activity by DFT and MD simulations.

Authors:  Y Sheena Mary; Y Shyma Mary; Anna Bielenica; Stevan Armaković; Sanja J Armaković; Vivek Chandramohan; Manjunath Dammalli
Journal:  J Mol Model       Date:  2021-07-03       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.